ClinicalTrials.Veeva
Menu

Find clinical trials for Breast Cancer in Taipei City

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Triple Negative Breast Cancer
Cancer
Carcinoma
Endometrial Cancer
Non-Small-Cell Lung Carcinoma
Ovarian Cancer
Squamous Cell Carcinoma of Head and Neck

Breast Cancer trials near Taipei City, TWN:

Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer Patients (ESCALATE)

Breast cancer (BC), especially premenopausal, is emerging rapidly in East Asia in recent 20 years. Half of the breast cancer...

Enrolling
Triple Negative Breast Cancer
Premenopausal Breast Cancer
Drug: Goserelin Acetate 3.6mg、Goserelin Acetate 10.8mg、Leuprolide Acetate 3.75mg、Leuprorelin Acetate 22.5mg、Triptorelin pamoate 11.25mg、Triptorelin pamoate 22.5mg

Phase 2

National Taiwan University
National Taiwan University

Taipei, Taiwan

DESTINY-Breast07 will investigate the safety, tolerability, and anti-tumour activity of trastuzumab deruxtecan (T-DXd) in combination with o ...

Active, not recruiting
Metastatic Breast Cancer
Drug: Tucatinib
Drug: Durvalumab

Phase 1, Phase 2

AstraZeneca
AstraZeneca

Taipei, Taiwan and 71 other locations

Chemotherapy-associated side-effects would affect therapeutic effect, quality of life, and cause permanent harm to breast cancer pa ...

Enrolling
Breast Cancer
Other: Placebo
Dietary Supplement: Probiotic
GenMont Biotech

Taipei, Taiwan

Recently updated

look at the efficacy and safety of trastuzumab deruxtecan (T-DXd) in a neoadjuvant setting, in high-risk, HER2-positive early non-metastatic breast...

Active, not recruiting
HER2-positive Early Breast Cancer
Breast Cancer
Drug: Pertuzumab
Drug: Paclitaxel

Phase 3

AstraZeneca
AstraZeneca

Taipei, Taiwan and 145 other locations

DESTINY-Breast 08 will investigate the safety, tolerability, PK and preliminary anti-tumour activity of T-DXd in combination with other ther ...

Active, not recruiting
Metastatic Breast Cancer
Drug: Fulvestrant
Drug: Durvalumab

Phase 1

AstraZeneca
AstraZeneca

Taipei, Taiwan and 36 other locations

Olaparib, a PARP inhibitor, is proven as an effective therapy for germline BRCA1/2-mutated breast cancer; however, the therapeutic ...

Enrolling
Metastatic Breast Cancer
Drug: Olaparib
Drug: Chemotherapy drug

Phase 2

National Taiwan University
National Taiwan University

Taipei, Please Select, Taiwan and 2 other locations

ribociclib or abemaciclib with letrozole) in people with breast cancer:* HR-positive (breast cancer cells that ne...

Enrolling
Breast Cancer
Drug: PF-07220060
Drug: letrozole

Phase 3

Pfizer
Pfizer

Taipei, Taiwan and 85 other locations

A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer....

Active, not recruiting
Advanced Breast Cancer
Drug: ARV-471
Drug: Fulvestrant

Phase 3

Pfizer
Pfizer

Taipei, Taiwan and 446 other locations

in combination with novel oncology therapies with or without paclitaxel and durvalumab + paclitaxel for first-line metastatic triple negative breast...

Active, not recruiting
Triple Negative Breast Neoplasms
Drug: Capivasertib
Drug: Trastuzumab deruxtecan

Phase 1, Phase 2

AstraZeneca
AstraZeneca

Taipei, Taiwan and 31 other locations

how treatment with Fulvestrant (FASLODEX) or Anastrozole (ARIMIDEX) effects disease progression for women with locally advanced or metastatic breast...

Active, not recruiting
Hormone Receptor Positive Breast Cancer
Drug: faslodex dummy
Drug: arimidex dummy

Phase 3

AstraZeneca
AstraZeneca

Taipei, Taiwan and 118 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems